STOP-NIDDM – Study to Prevent Non-Insulin-Dependent Diabetes Mellitus

Principal contacts

Markolf Hanefeld - Technical University Dresden, Dresden, Germany

Study design

The Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) is a two-arm clinical trial based in Dresden, Germany and is a substudy of a the larger STOP-NIDDM study based at hospitals in Germany, Austria, Norway, Denmark, Sweden, Finland, Israel, and Spain. The principal aim of the trial was to investigate the effect of Acarbose (100mg/day) versus placebo on risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. Individuals were eligible for inclusion if they were aged between 40 and 70 years, with a BMI between 25 and 40kg/m², had impaired glucose tolerance, and fasting plasma glucose concentration between 100 and 140mg/dL. The protocol was approved by appropriate Institutional Review Boards and every patient signed an informed consent form.


Key publications

Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose Tolerance. Stroke. 2004 May;35(5):1073-8